Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1994 Sep 1;151(5):537–542.

Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

M J Gribble 1
PMCID: PMC1337188  PMID: 8069799

Abstract

OBJECTIVE: To offer guidelines for the use of cefotetan, a cephamycin antibiotic, in order to minimize its overprescription. OPTIONS: Clinical practice options considered were treatment of infections with the use of second- and third-generation cephalosporins, carbapenems such as imipenem as well as combination regimens of agents active against anaerobic bacteria, such as metronidazole or clindamycin with an aminoglycoside. OUTCOMES: In order of importance: efficacy, side effects and cost. EVIDENCE: A MEDLINE search of articles published between January 1982 and December 1993. In-vitro and pharmacokinetic studies published in recognized peer-reviewed journals that used recognized standard methods with appropriate controls were reviewed. For results of clinical trials, the reviewers emphasized randomized double-blind trials with appropriate controls. VALUES: The Antimicrobial Agents Committee of the Canadian Infectious Disease Society (CIDS) and a recognized expert (M.J.G.) recommended use of cefotetan to prevent and treat infections against which it has proved effective in randomized controlled trials. BENEFITS, HARMS AND COSTS: These guidelines should lead to less inappropriate prescribing of cefotetan, with its attendant costs and risk of development of resistant bacteria. RECOMMENDATIONS: Cefotetan could be considered an alternative single agent for prophylaxis of infection in patients undergoing elective bowel surgery. It may be used to treat patients with acute pelvic inflammatory disease and endometritis. VALIDATION: This article was prepared, reviewed and revised by the Committee on Antimicrobial Agents of the CIDS. It was then reviewed by the Council of the CIDS, and any further necessary revisions were made by the chairman of the committee.

Full text

PDF
537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrose N. S., Johnson M., Burdon D. W., Keighley M. R. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother. 1985 Mar;15(3):319–326. doi: 10.1093/jac/15.3.319. [DOI] [PubMed] [Google Scholar]
  2. Ayers L. W., Jones R. N., Barry A. L., Thornsberry C., Fuchs P. C., Gavan T. L., Gerlach E. H., Sommers H. M. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Antimicrob Agents Chemother. 1982 Nov;22(5):859–877. doi: 10.1128/aac.22.5.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry A. L. Criteria for in vitro susceptibility testing of cefotetan. Correlations with clinical and bacteriologic responses. Am J Surg. 1988 May 31;155(5A):24–29. doi: 10.1016/s0002-9610(88)80208-3. [DOI] [PubMed] [Google Scholar]
  4. Barry A. L., Jones R. N. Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin. J Clin Microbiol. 1987 Aug;25(8):1570–1571. doi: 10.1128/jcm.25.8.1570-1571.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Berkeley A. S., Freedman K. S., Ledger W. J., Orr J. W., Benigno B. B., Gordon S. F., McGregor J. A., Galask R. P., Sevin B. U. Comparison of cefotetan and cefoxitin prophylaxis for abdominal and vaginal hysterectomy. Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):706–709. doi: 10.1016/s0002-9378(16)44531-x. [DOI] [PubMed] [Google Scholar]
  6. Bloomberg R. J. Cefotetan-induced anaphylaxis. Am J Obstet Gynecol. 1988 Jul;159(1):125–126. doi: 10.1016/0002-9378(88)90506-6. [DOI] [PubMed] [Google Scholar]
  7. Brook I. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice. J Infect Dis. 1989 Oct;160(4):651–656. doi: 10.1093/infdis/160.4.651. [DOI] [PubMed] [Google Scholar]
  8. Browning M. J., Holt H. A., White L. O., Chapman S. T., Banks R. A., Reeves D. S., Yates R. A. Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis. J Antimicrob Chemother. 1986 Jul;18(1):103–106. doi: 10.1093/jac/18.1.103. [DOI] [PubMed] [Google Scholar]
  9. Carlson C., Duff P. Antibiotic prophylaxis for cesarean delivery: is an extended-spectrum agent necessary? Obstet Gynecol. 1990 Sep;76(3 Pt 1):343–346. [PubMed] [Google Scholar]
  10. Carver P. L., Nightingale C. H., Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother. 1989 Jan;23(1):99–106. doi: 10.1093/jac/23.1.99. [DOI] [PubMed] [Google Scholar]
  11. Conjura A., Bell W., Lipsky J. J. Cefotetan and hypoprothrombinemia. Ann Intern Med. 1988 Apr;108(4):643–643. doi: 10.7326/0003-4819-108-4-643_1. [DOI] [PubMed] [Google Scholar]
  12. Cornick N. A., Cuchural G. J., Jr, Snydman D. R., Jacobus N. V., Iannini P., Hill G., Cleary T., O'Keefe J. P., Pierson C., Finegold S. M. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J Antimicrob Chemother. 1990 Jun;25(6):1011–1019. doi: 10.1093/jac/25.6.1011. [DOI] [PubMed] [Google Scholar]
  13. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988 May;32(5):717–722. doi: 10.1128/aac.32.5.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group. Antimicrob Agents Chemother. 1990 Mar;34(3):479–480. doi: 10.1128/aac.34.3.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dias M. B., Jacobus N. V., Tally F. P., Gorbach S. L. Activity of cefotetan against anaerobic bacteria. Diagn Microbiol Infect Dis. 1986 Apr;4(4):359–363. doi: 10.1016/0732-8893(86)90079-9. [DOI] [PubMed] [Google Scholar]
  16. Drumm J., Donovan I. A., Wise R. A comparison of cefotetan and cephazolin for prophylaxis against wound infection after elective cholecystectomy. J Hosp Infect. 1985 Sep;6(3):277–280. [PubMed] [Google Scholar]
  17. Faro S., Martens M. G., Hammill H. A., Riddle G., Tortolero G. Antibiotic prophylaxis: is there a difference? Am J Obstet Gynecol. 1990 Apr;162(4):900–909. doi: 10.1016/0002-9378(90)91290-s. [DOI] [PubMed] [Google Scholar]
  18. Fry D. E. Cefotetan: a perspective for the surgical patient. Am J Surg. 1988 May 31;155(5A):108–110. doi: 10.1016/s0002-9610(88)80225-3. [DOI] [PubMed] [Google Scholar]
  19. Guibert J., Kitzis M. D., Yvelin C., Acar J. F. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers. J Antimicrob Chemother. 1983 Jan;11 (Suppl):201–206. doi: 10.1093/jac/11.suppl_a.201. [DOI] [PubMed] [Google Scholar]
  20. Hemsell D. L., Wendel G. D., Gall S. A., Newton E. R., Gibbs R. S., Knuppel R. A., Lane T. W., Sweet R. L. Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections. Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):722–727. doi: 10.1016/s0002-9378(16)44535-7. [DOI] [PubMed] [Google Scholar]
  21. Holt J. Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients. Arch Surg. 1988 Apr;123(4):523–523. doi: 10.1001/archsurg.1988.01400280137028. [DOI] [PubMed] [Google Scholar]
  22. Jagelman D. G., Fabian T. C., Nichols R. L., Stone H. H., Wilson S. E., Zellner S. R. Single-dose cefotetan versus multiple-dose cefoxitin as prophylaxis in colorectal surgery. Am J Surg. 1988 May 31;155(5A):71–76. doi: 10.1016/s0002-9610(88)80217-4. [DOI] [PubMed] [Google Scholar]
  23. Jones R. N. Cefotetan: a review of the microbiologic properties and antimicrobial spectrum. Am J Surg. 1988 May 31;155(5A):16–23. doi: 10.1016/s0002-9610(88)80207-1. [DOI] [PubMed] [Google Scholar]
  24. Kaiser C. W., McAuliffe J. D., Barth R. J., Lynch J. A. Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan. Arch Surg. 1991 Apr;126(4):524–525. doi: 10.1001/archsurg.1991.01410280128021. [DOI] [PubMed] [Google Scholar]
  25. Leaper D. J., Cooper M. J., Turner A. A comparative trial between cefotetan and cephazolin for wound sepsis prophylaxis during elective upper gastrointestinal surgery with an investigation of cefotetan penetration into the obstructed biliary tree. J Hosp Infect. 1986 May;7(3):269–276. doi: 10.1016/0195-6701(86)90077-0. [DOI] [PubMed] [Google Scholar]
  26. Lewis R. T., Duma R. J., Echols R. M., Jemsek J. G., Najem A. Z., Press R. A., Stone H. H., Ton G. T., Wilson S. E. Comparative study of cefotetan and cefoxitin in the treatment of intra-abdominal infections. Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):728–735. doi: 10.1016/s0002-9378(16)44536-9. [DOI] [PubMed] [Google Scholar]
  27. Mauro L. S., Mauro V. F., Miller P. C., Lacher D. A. Effect of cefotetan on creatinine determination by the picric acid and enzymatic methods. Clin Pharm. 1989 Jul;8(7):505–508. [PubMed] [Google Scholar]
  28. McCloskey R. V. Spontaneous reports of bleeding: comparison of N-methylthiotetrazole side chain (MTT) and non-MTT cephalosporins. J Infect Dis. 1988 Dec;158(6):1405–1405. doi: 10.1093/infdis/158.6.1405. [DOI] [PubMed] [Google Scholar]
  29. McGregor J. A., Gordon S. F., Krotec J., Poindexter A. N. Results of a randomized, multicenter, comparative trial of a single dose of cefotetan versus multiple doses of cefoxitin as prophylaxis in cesarean section. Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):701–706. doi: 10.1016/s0002-9378(16)44530-8. [DOI] [PubMed] [Google Scholar]
  30. Periti P., Mazzei T., Tonelli F. Single-dose cefotetan vs. multiple-dose cefoxitin--antimicrobial prophylaxis in colorectal surgery. Results of a prospective, multicenter, randomized study. Dis Colon Rectum. 1989 Feb;32(2):121–127. doi: 10.1007/BF02553824. [DOI] [PubMed] [Google Scholar]
  31. Probst J. R., Benrubi G. I., Sanchez-Ramos L., Todd M. Comparison of one dose cefazolin versus one dose cefotetan for cesarean section prophylaxis. J Fla Med Assoc. 1989 Dec;76(12):1027–1029. [PubMed] [Google Scholar]
  32. Shevchuk Y. M., Conly J. M. Antibiotic-associated hypoprothrombinemia: a review of prospective studies, 1966-1988. Rev Infect Dis. 1990 Nov-Dec;12(6):1109–1126. [PubMed] [Google Scholar]
  33. Smith B. R., LeFrock J. L., Thyrum P. T., Doret B. A., Yeh C., Onesti G., Schwartz A., Zimmerman J. J. Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Antimicrob Agents Chemother. 1986 May;29(5):887–893. doi: 10.1128/aac.29.5.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sweet R. L., Gall S. A., Gibbs R. S., Hemsell D. L., Knuppel R. A., Lane T. W., Miller R. D., Newton E. R., Poindexter A. N., Reguero W. Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections. Am J Surg. 1988 May 31;155(5A):56–60. doi: 10.1016/s0002-9610(88)80214-9. [DOI] [PubMed] [Google Scholar]
  35. Sweet R. L., Schachter J., Landers D. V., Ohm-Smith M., Robbie M. O. Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline. Am J Obstet Gynecol. 1988 Mar;158(3 Pt 2):736–741. doi: 10.1016/s0002-9378(16)44537-0. [DOI] [PubMed] [Google Scholar]
  36. Ward A., Richards D. M. Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Nov;30(5):382–426. doi: 10.2165/00003495-198530050-00002. [DOI] [PubMed] [Google Scholar]
  37. Wexler H. M., Finegold S. M. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother. 1988 Apr;32(4):601–604. doi: 10.1128/aac.32.4.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wilson S. E., Boswick J. A., Jr, Duma R. J., Echols R. M., Jemsek J. G., Lerner R., Lewis R. T., Najem A. Z., Press R. A., Rittenbury M. S. Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin. Am J Surg. 1988 May 31;155(5A):61–66. doi: 10.1016/s0002-9610(88)80215-0. [DOI] [PubMed] [Google Scholar]
  39. Wurtz R. M., Sande M. A. Cefotetan and coagulopathy. J Infect Dis. 1989 Sep;160(3):555–556. doi: 10.1093/infdis/160.3.555a. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES